Veracyte (VCYT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

VCYT Veracyte

Watchlist

33.130
-0.910-2.67%

Close Oct 1 16:00 ET

32.630
-0.500-1.51%

Pre 04:40 ET

2.54BMarket Cap-44770P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Scotiabank Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $40
Moomoo NewsSep 30 08:34 ET · Ratings
Scotiabank Sticks to Their Buy Rating for Veracyte (VCYT)
TipRanksSep 30 08:15 ET · Ratings
Express News | Veracyte Inc : Scotiabank Raises Target Price to $40 From $37
ReutersSep 27 07:27 ET
Veracyte Director Jones Sells Over $182,000 in Company Stock
InvestingSep 23 16:28 ET
Express News | Veracyte Inc - Data Support Company's Plan to Expand Decipher Prostate Test to Patients With Metastatic Disease
ReutersSep 15 08:57 ET
New Data Presented at ESMO 2024 Show That Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients With Metastatic Prostate Cancer
Yahoo FinanceSep 15 08:45 ET

Comments

Stock_Drift

Sep 15 09:56

$Veracyte (VCYT.US)$

ClydePeternuts

Sep 12 02:17

Cathie Wood and Ark Invest's trade activity from today 9/10
$ARK Innovation ETF (ARKK.US)$ :
Bought $Advanced Micro Devices (AMD.US)$ $DraftKings (DKNG.US)$ $Tempus AI (TEM.US)$
Sold $Unity Software (U.US)$ $Palantir (PLTR.US)$ $Twist Bioscience (TWST.US)$ $Veracyte (VCYT.US)$
By the way..
Palantir $PLTR is on fire this year
It's up over 109% YTD, just got included in the S&P500, and today Bank of America raised their price target to $50 a share
D. E. Shaw owns almost $500 million worth of shares, more than any...

Moomoo AI

Feb 24 08:25

Analysts are slightly more optimistic about Veracyte's losses per share, but expect its revenue growth to slow down substantially compared to its historical 29% growth rate. The wider industry is expected to outpace Veracyte.

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Moomoo AI

Oct 28, 2023 08:07

The absence of any insider transactions in the past three months doesn't reveal much. Low insider ownership and previous insider selling at Veracyte sparks less enthusiasm. Investors should be aware of potential risks associated with the company.